Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
IMO... Inven2 have seen no return in the Blood pressure patents since 2014 and perhaps didn't see one anytime soon. Again IMO... Its been a good move on PXS part. Get the IP when there is very little value in the patents and before a "£4bn listed Chinese dietary supplement business" puts some value on it.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020077747&_cid=P22-KDTXX5-78957-1
https://patentscope.wipo.int/search/en/detail.jsf?docId=CN238963528&_cid=P22-KDTXX5-78957-1
One thing that does strike me from the RNS is that why would Oslo accept shares for payment of something they could have held out for hard cash for, unless they were confident (given what they know) that the share price is only going in one direction. #justsayin
But it isn't though! Colchester branch do not stock it;not avaliable to click collect
Nothing is being done with regard to Covid...
More duff FB posts written by IF... Advertising!!!!
FF is produced in batches on production schedule and FF+O is produced on min order basis.
DSM does not manufacture either its all outsourced. Covid lockdown interrupted supply chains hence production delays.
Nothing new in this RNS apart from patent confirmations which are quite telling.
The rns states (further down the page) "The product is also available to purchase from Amazon.co.uk and from Holland & Barrett" so I don't think the problem is at provexis side.
I'll phone the mobile number on the RNS and leave a message; will let you know x
Maybe you should ask Amazon and h&b that question
Agreed;but why not available on Amazon or HB?
It's a step forwards having confirmation of the link between the circulatory benefits of Fruitflow against the damage caused by Covid. Someone has to pick up the claim and attach it to a commercial product. Will the first be Provexis with Fruitflow +Omega3 ? If so, then a much larger inventory would be needed, and they talk of supply chain delay in this update. Could current production match a big upturn in demand? hopefully minds are being concentrated around that issue.
Alliance News) - Provexis PLC on Thursday announced that it will purchase the antihypertensive intellectual property and patents from Inven2 AS and has seen increased demand for its product due Covid-19.
The Berkshire, England-based food technology company said it has agreed to buy the patents from Inven2 for 11.5 million shares in the company, at 0.69 pence each, totalling about GBP79,350.
Provexis shares were up 5.7% at 0.72 pence each on Thursday afternoon in London.
Inven2 is the University of Oslo's technology transfer office.
The intellectual property holds significant value to the Provexis as its main product, Fruitflow, which is a natural extract from tomatoes used to fight cardiovascular disease, was collaboratively researched between the University of Oslo and the company.
Provexis Chief Executive Ian Ford said: "We are delighted to have secured outright ownership of this important blood pressure lowering patent family, and would like to thank the University of Oslo for their support and assistance throughout the collaboration."
Provexis also said that it has experienced increased consumer interest for Fruitflow in light of the Covid-19 pandemic, as consumers look to nutritional interventions to help them fortify the circulatory system against the effects of Covid-19. Fruitflow helps with normal blood flow and circulation whilst Covid-19 can have an adverse effect on circulation.
Perhaps they have just tipped into profit ,hence trading update !
On what basis do you make that observation?
Alf - judging by the other Covid stocks I’m in, the answer to your question is no.
Your ‘certainty’ on both aspects is unfounded
Having full ownership of the BP IP is plainly good news. Depending on your point of view, viewing Oslo's share of that IP at 80k at yesterdays's share price could be good or bad. Good because it means next to no dilution to settle it, but bad because, well 80k isn't very much and doesn't exactly value that IP very much I'd caveat that by saying, firstly, I don't know what percentage split of the IP that 80k applies to, and also by saying that if Oslo hang onto those shares and the sp rises, then their return obviously rises too, but there's no way of knowing if they'll do that.
The COVID statement ( excluding the bit about supply issues ) is suitably vague and could mean anything between nothing and a massive opportunity.
With less than seven weeks to go to the publication of the Annual Report, mention of a further trading update is just weird. If there's price sensitive info to be released, then why not release it today ? If it's not price sensitive info then why not wait until you put the report out and include it in a post reporting period section ? Again, it could be anything ranging from positive news on the Bi-Health front to a fund raising, neither of which seem desperately likely in the next six or seven weeks, but wtfdIk.
Plainly we'll find out more by the end of September at the latest.
BB
Don't you think this update emphasises how much confidentiality Provexis has to respect?
I am certain that there is a lot of work on the Covid subject, but also certain that it just can't be discussed. So we have to suffer the old duffer saying they are doing nothing, whilst the reverse is the case.
An important piece of housekeeping..........I reckon bi-health must be close now and this was a sticking point, so they advised PXS to get it sorted.
The covid news is very belated but welcome nonetheless.
Trading update will be of more interest though..............i'm not expecting fireworks but hopefully steady progress. The company could still do with a bit more impetus (or a rocket up the backside)
Most the people posting here are in their 80's and have Dementia, no work for them.
Sphincter, I meant back to sleep for Provexis whilst we wait on transformational news (about 5 years late LOL! )
FFS Colby it’s 9 o’clock do you do any work you lazy git.
Oslo University is Dr Asim's manor these days, so not at all surprising that they have developed further IP. Seems fair to me that the company pays in shares, hopefully these will be held so that they can share in the benefits of their labours.
AIM rules state results have to be issued no later than 6 months after year end, so no later than 30th September.
Sphinx, there was a trading update last year in July. This year will probably be cut & paste as usual and it looks as if the finals will be as late as possible. Market reaction to today's RNS as expected. A few more patents to add to the vast collection and paid for by more dilution, (It wasn't exactly expensive was it so it can't be that great!)
Good to see a belated mention of Covid-19 though.
Back to sleep. Nothing to see here.
The Company's Fruitflow+ Omega-3 direct selling business has been operating largely as normal throughout the pandemic, and despite some initial delays in the supply chain a new production run of Fruitflow+ Omega-3 capsules has just been completed thus ensuring continued supply of the product.
The Company will issue a full trading update in due course.
Oh dear, no 0.35 buy in. Strong strong strong strong bu.............y